#Japan #Tokyo #Longevity #Regenesome #Space Seed

Regenesome's Recent Funding and Future Plans

In a significant move to bolster its research capabilities, Regenesome, a subsidiary of Space Seed Holdings based in Minato, Tokyo, has successfully secured 20 million yen through J-KISS-style convertible bonds from Livanes Capital. This funding, finalized in August 2025, is aimed at bridging the gap for a more extensive Series A funding round anticipated in October 2025.

Background of the Funding

Regenesome is on a mission to provide technologies necessary for aging prevention, pivotal for human habitation on the lunar surface by 2040. This mission is being pursued through cutting-edge research and development at its recently established innovation hub, the Regenesome Takanawa Longevity Lab located in the TAKANAWA GATEWAY CITY of Minato, Tokyo, which opened its doors on May 13, 2025.

The funds from this recent financing round will not only support ongoing research but will also be utilized for collaborations with esteemed institutions such as Tohoku University, Tokyo University of Science, Good Hero Therapeutics, and Sky Pharma, among others. Regenesome aims to accelerate projects related to epigenetic clocks and the development of the 'SAISEI' supplement as well as to further research into the Longevity Room, utilizing low-oxygen environments.

In the past, Regenesome has successfully conducted various rounds of fundraising, including 80 million yen from Japan System Technology (JAST) in October 2024 and a loan of 30 million yen from a city bank in May 2025, bringing the total funds raised to approximately 110 million yen before this latest injection of 20 million yen.

Future Prospects

Looking ahead, Regenesome plans to engage in its Series A funding round from October 2025 to March 2026, leveraging these funds over the next few years until 2029 to fulfill several objectives:

• - Expanding research contract operations
• - Launching three healthcare products into the market while validating product-market fit (PMF)
• - Conducting non-clinical trials within the medical field
• - Pursuing mergers and acquisitions (M&A) within the life sciences sector
• - Investing in longevity-oriented companies with potential for collaborative projects

Investments and Innovations

In a comment from Mr. Chihiro Hanai, a director at Livanes Inc., he emphasized the importance of the mission at hand. He stated, “While we often refer to a 100-year lifespan, hearing about the ambitious vision from Mr. Suzuki regarding space exploration has compelled me to challenge myself even more. I trust that specific developments in applicable aging prevention technologies will ignite exciting projects involving diverse participants. Unlike currency, knowledge increases when shared and enriches the world through exchange. Let’s foster an ecosystem of knowledge through the LiSH Lab at Takanawa.”

Regenesome’s CEO, Mr. Kengo Suzuki, also expressed the company's determination to push forward with research and commercialization after this funding round, aiming to deliver products in aging care and advance into cutting-edge medical technologies, including space medicine. He stated, “Together with our investors, including Livanes Capital, we will steadfastly advance towards our vision of demonstrating technology by 2030 and expanding human habitation on the lunar surface by 2040.”

About Regenesome

Regenesome is focused on leveraging nanoparticles, including exosomes, to provide innovative solutions for aging suppression and regenerative medicine. With the establishment of the Takanawa Longevity Lab in May 2025, the company is set to accelerate both business and research development. The ultimate goal is to establish new solutions within medical technology, particularly in space medicine, contributing to extended health spans and aiding humanity's endeavors into outer space. For more information, please visit their website: Regenesome.

About Space Seed Holdings

Space Seed Holdings pursues its mission of turning science fiction into reality through investment activities, research, and business creation. The company spearheads programs like the Fermentation and Longevity Fund, aimed at socially implementing fermentation and longevity technologies. By 2040, they aspire to assemble the necessary technologies for human habitation in outer space, collaborating with various stakeholders. To learn more, visit Space Seed Holdings.